Sexual Health Supplement Market Set to Expand 40% Through 2030

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Sexual health supplement market projected to grow 40% to $5.31 billion by 2030, driven by consumer wellness awareness and demand for natural, personalized products.

Sexual Health Supplement Market Set to Expand 40% Through 2030

The global sexual health supplement market is poised for significant expansion, with projections indicating growth from $3.79 billion in 2026 to $5.31 billion by 2030, representing a compound annual growth rate of 8.8%. This expansion is underpinned by several converging market dynamics, including heightened consumer awareness regarding sexual wellness, increasing preference for natural and plant-based formulations, and the proliferation of personalized supplement offerings tailored to individual health profiles.

Industry developments reflect evolving consumer expectations around product transparency and efficacy. Market participants are investing in innovative delivery mechanisms, including functional gummies and other novel formats, while expanding gender-specific product lines designed to address distinct physiological needs. Enhanced ingredient traceability and verification protocols are becoming standard competitive differentiators as consumers demand greater accountability from manufacturers regarding sourcing and quality standards.

The Asia Pacific region commands the largest market share, reflecting broader demographic trends and growing health consciousness in the region. Established pharmaceutical and wellness companies including Pfizer, GlaxoSmithKline, and Amway maintain significant market positions, while the shift toward direct-to-consumer e-commerce channels continues to reshape distribution strategies and consumer accessibility across global markets.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 20

Related Coverage

GlobeNewswire Inc.

Valneva Plunges 37% After Lyme Vaccine Fails Phase 3 Trial; Law Firm Launches Investigation

Valneva stock plummets 37% after Phase 3 Lyme vaccine candidate fails trial; law firm investigates potential securities fraud claims.

PFEVALN
GlobeNewswire Inc.

Serina Therapeutics to Showcase POZ Platform at Roth Conference

Clinical-stage biotech **Serina Therapeutics** will present at 38th Annual Roth Conference on March 24, 2026, highlighting its proprietary POZ Platform technology and pipeline.

PFESER
Benzinga

Lyme Vaccine Setback: Valneva-Pfizer Trial Misses Primary Goal But Eyes Regulatory Path

Valneva-Pfizer Lyme vaccine trial misses primary endpoint but shows 73-75% secondary efficacy; Pfizer to seek regulatory approval despite setback. Valneva shares fell 35.27%.

PFEVALN
GlobeNewswire Inc.

Fumed Silica Market Set to Reach $2.14B by 2030 on Strong Industrial Demand

Global fumed silica market projected to grow 3.46% annually through 2030, reaching $2.14 billion. Automotive and EV adoption lead growth drivers.

CBT
The Motley Fool

Pharma Giant and Healthcare Insurer Offer Entry Points for Long-Term Investors

Pfizer and UnitedHealth Group present buying opportunities for $500 investors. Pfizer trades at 9x forward earnings with oncology growth plans; UnitedHealth at 15x after cost-cutting initiatives.

PFEUNH
GlobeNewswire Inc.

Biotech Veteran Ramanayake Takes Helm at Anaveon as Immune Reprogramming Firm Pursues Clinical Trials

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.

PFENVSBNTX